Navigation Links
Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
Date:4/18/2013

LONDON, April 18, 2013 /PRNewswire/ -- Replikins Ltd will reveal details on the availability of two completely synthetic vaccine candidates, both with long-term prevention goals and acute short-term blocking capacity.  One of these vaccines targets H7N9 alone, the other for H7N9 plus the other common influenza strains. The company is exploring partnerships with established healthcare and pharmaceutical companies to aggressively commercialize the technology. 

Because Replikins is leveraging proprietary software techniques to isolate targeted regions in the virus, combined with recent advances in manufacturing synthetic peptides, the company and its partners are able to provide rapid turnaround of vaccine candidates based on early data emerging from disease outbreaks.  This approach stands in marked contrast to projections by other companies of delays of seven months or longer before vaccines can be made available, and makes it possible to consider effective public health responses to disease outbreaks while they are still at an early stage.

Replikins will provide details of the technology and is seeking partnerships at the BIO International Convention April 22nd-25th at its booth #3456, McCormick Place, Chicago.

The technique used to create Replikins' new synthetic vaccine candidates is similar to those the company used in manufacturing a successful Replikins H5N1 "bird flu" vaccine in chickens in a paper published in 2009.  That vaccine was produced in 7 days, shipped freeze-dried, and administered via the respiratory tract.  Significantly, in addition to stopping the virus in the chickens, excretion of the virus was completely prevented, thus potentially interfering with the build-up of virus reservoirs which encourage mutations.

Contact: Dr. Samuel Bogoch , 646-320-5910, Email

References:

1.  Nature Precedings.  Bogoch et al, doi:10.1038/npre.2012.6952.1

(see also seven additional  Nature Precedings Publications, Bogoch 2011-2012. http://precedings.nature.com/users/549471c7b195af1864d2f1b1996f60642.

2.  www.replikins.com

3. Dr. Sanjay Gupta of CNN Reports on Replikins (www.replikins.com)

4. Jackwood et al. Avian Diseases 53(4): 613‐617, 2009

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New White Paper Details What Compounding Pharmacies Must Know to Prepare for FDA Inspections
2. CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial Results
3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
4. Generex Announces Details of Investor Conference Call
5. White Paper Details Five Things to Consider Before Buying Spiral Bevel Gear Drives
6. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
7. New Report Details NCPA Efforts to Drive Greater Medication Adherence
8. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
9. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
10. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
11. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)...  The U.S. Food and Drug Administration today granted ... adults and pediatric patients 12 years and older with ... not received prior chemotherapy. This is the first FDA-approved ... skin cancer. "While skin cancer is one ... form called Merkel cell cancer have not had an ...
(Date:3/23/2017)... AUSTIN, Texas , March 23, 2017 /PRNewswire/ ... www.digitalpharmacist.com ), a rapidly growing digital ... PocketRx, a mobile app that allows patients to ... including multi-store locations such as Denver Health Pharmacy, ... app. The acquisition helps Digital Pharmacist accelerate its ...
(Date:3/23/2017)... , March 23, 2017  Interpace Diagnostics Group, ... a fully integrated commercial company that provides clinically ... announced that it has entered into agreements to ... RedPath Shareholders ("RedPath") and concurrently terminate its royalty ... outstanding secured debt to RedPath amounting to $9.34 ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... A recent report from the National Council on Teacher ... NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at 221 ... the U.S. It argues that this higher bar should be set by states, by ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy ... 960 Gruene Road in Building 2. The clinic is the group’s second in New ... says opening the company’s second New Braunfels location brings things full circle for the ...
(Date:3/23/2017)... ... , ... The MBI “Hall of Fame” recognizes the contributions of those whose careers are or ... the careers of all others involved. , On Monday, March 21st, 2017 Laurie ... of Fame. The induction took place during the World of Modular – Award Gala ...
(Date:3/23/2017)... TX (PRWEB) , ... March 23, 2017 , ... March ... organs that pack a punch when it comes to maintaining good health. Every day, ... 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating fluid ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Angeles based healthcare technology company California Healthcom Group (CHG). , The HUG ... healthcare arena. With headquarters in California, CHG is a growing, internationally recognized healthcare ...
Breaking Medicine News(10 mins):